JPH0637520B2
(ja)
|
1985-07-03 |
1994-05-18 |
味の素株式会社 |
ポリペプチド
|
AU597574B2
(en)
|
1986-03-07 |
1990-06-07 |
Massachusetts Institute Of Technology |
Method for enhancing glycoprotein stability
|
US4973577A
(en)
|
1986-04-04 |
1990-11-27 |
The Salk Institute For Biological Studies |
FSH-releasing peptides
|
US5080891A
(en)
|
1987-08-03 |
1992-01-14 |
Ddi Pharmaceuticals, Inc. |
Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
US5096815A
(en)
|
1989-01-06 |
1992-03-17 |
Protein Engineering Corporation |
Generation and selection of novel dna-binding proteins and polypeptides
|
US5198346A
(en)
|
1989-01-06 |
1993-03-30 |
Protein Engineering Corp. |
Generation and selection of novel DNA-binding proteins and polypeptides
|
US5078486A
(en)
|
1989-10-13 |
1992-01-07 |
Evans David W |
Self-calibrating vision test apparatus
|
AU8761391A
(en)
|
1990-09-13 |
1992-04-15 |
Children's Hospital Medical Center Of Northern California |
Method for increasing red blood cell production by treatment with activin or activin-related peptides
|
US5208219A
(en)
|
1991-02-14 |
1993-05-04 |
Celtrix Pharmaceuticals Inc. |
Method for inducing bone growth
|
US5118667A
(en)
|
1991-05-03 |
1992-06-02 |
Celtrix Pharmaceuticals, Inc. |
Bone growth factors and inhibitors of bone resorption for promoting bone formation
|
EP0542971A1
(en)
|
1991-05-10 |
1993-05-26 |
The Salk Institute For Biological Studies |
CLONING AND RECOMBINANT PRODUCTION OF RECEPTOR(S) OF THE ACTIVIN/TGF-$g(b) SUPERFAMILY
|
US5885794A
(en)
|
1991-05-10 |
1999-03-23 |
The Salk Institute For Biological Studies |
Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-β superfamily
|
US6162896A
(en)
|
1991-05-10 |
2000-12-19 |
The Salk Institute For Biological Studies |
Recombinant vertebrate activin receptors
|
US20050186593A1
(en)
|
1991-05-10 |
2005-08-25 |
The Salk Institute For Biological Studies |
Cloning and recombinant production of CRF receptor(s)
|
US6287816B1
(en)
|
1991-06-25 |
2001-09-11 |
Genetics Institute, Inc. |
BMP-9 compositions
|
KR100255415B1
(ko)
|
1991-06-25 |
2000-05-01 |
브루스 엠. 에이센 |
비엠피-9 조성물
|
US6692925B1
(en)
|
1992-11-17 |
2004-02-17 |
Ludwig Institute For Cancer Research |
Proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their use
|
EP1475440A3
(en)
|
1993-01-12 |
2004-11-17 |
The Johns Hopkins University School Of Medicine |
Growth differentiation factor-3
|
US5637480A
(en)
|
1993-05-12 |
1997-06-10 |
Genetics Institute, Inc. |
DNA molecules encoding bone morphogenetic protein-10
|
KR100231640B1
(ko)
|
1993-05-12 |
1999-12-01 |
토마스 제이 데스로저 |
Bmp-10 조성물
|
US5677196A
(en)
|
1993-05-18 |
1997-10-14 |
University Of Utah Research Foundation |
Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
|
US5831050A
(en)
|
1993-06-07 |
1998-11-03 |
Creative Biomolecules, Inc. |
Morphogen cell surface receptor
|
ATE355369T1
(de)
|
1993-10-14 |
2006-03-15 |
Harvard College |
Verfahren zur induzierung und zur erhaltung neuronalen zellen
|
US5525490A
(en)
|
1994-03-29 |
1996-06-11 |
Onyx Pharmaceuticals, Inc. |
Reverse two-hybrid method
|
US5658876A
(en)
|
1994-04-28 |
1997-08-19 |
The General Hospital Corporation |
Activin antagonists as novel contraceptives
|
WO1996001845A1
(en)
|
1994-07-08 |
1996-01-25 |
The Johns Hopkins University School Of Medicine |
Growth differentiation factor-11
|
US5885574A
(en)
|
1994-07-26 |
1999-03-23 |
Amgen Inc. |
Antibodies which activate an erythropoietin receptor
|
US5545616A
(en)
|
1994-09-22 |
1996-08-13 |
Genentech, Inc. |
Method for predicting and/or preventing preterm labor
|
US5760010A
(en)
|
1995-01-01 |
1998-06-02 |
Klein; Ira |
Method of treating liver disorders with a macrolide antibiotic
|
US5814565A
(en)
|
1995-02-23 |
1998-09-29 |
University Of Utah Research Foundation |
Integrated optic waveguide immunosensor
|
NZ306767A
(en)
|
1995-04-11 |
2000-03-27 |
Univ Johns Hopkins |
Method of identifying molecular interactions employing counterselection and at least two hybrid molecules or two hybrid systems
|
EP0771873A3
(en)
|
1995-10-27 |
1998-03-04 |
Takeda Chemical Industries, Ltd. |
Neuronal cell-specific receptor protein
|
GB9526131D0
(en)
|
1995-12-21 |
1996-02-21 |
Celltech Therapeutics Ltd |
Recombinant chimeric receptors
|
US6004780A
(en)
|
1996-03-26 |
1999-12-21 |
Human Genome Sciences, Inc. |
Growth factor HTTER36
|
US20050244867A1
(en)
|
1996-03-26 |
2005-11-03 |
Human Genome Sciences, Inc. |
Growth factor HTTER36
|
EP0939816A1
(en)
|
1996-10-25 |
1999-09-08 |
G.D. SEARLE & CO. |
Circularly permuted erythropoietin receptor agonists
|
US6605699B1
(en)
|
1997-01-21 |
2003-08-12 |
Human Genome Sciences, Inc. |
Galectin-11 polypeptides
|
US6034062A
(en)
|
1997-03-13 |
2000-03-07 |
Genetics Institute, Inc. |
Bone morphogenetic protein (BMP)-9 compositions and their uses
|
US6231880B1
(en)
|
1997-05-30 |
2001-05-15 |
Susan P. Perrine |
Compositions and administration of compositions for the treatment of blood disorders
|
ATE417927T1
(de)
|
1997-07-30 |
2009-01-15 |
Univ Emory |
Neue knochenmineralisierungsproteine, dna, vektoren, expressionssysteme
|
US6696260B1
(en)
|
1997-08-01 |
2004-02-24 |
The Johns Hopkins University School Of Medicine |
Methods to identify growth differentiation factor (GDF) binding proteins
|
US6891082B2
(en)
|
1997-08-01 |
2005-05-10 |
The Johns Hopkins University School Of Medicine |
Transgenic non-human animals expressing a truncated activintype II receptor
|
WO1999006559A1
(en)
|
1997-08-01 |
1999-02-11 |
The Johns Hopkins University School Of Medicine |
Methods to identify growth differentiation factor (gdf) receptors
|
US6656475B1
(en)
|
1997-08-01 |
2003-12-02 |
The Johns Hopkins University School Of Medicine |
Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
|
CA2302525A1
(en)
|
1997-08-29 |
1999-03-04 |
Human Genome Sciences, Inc. |
Follistatin-3
|
US6953662B2
(en)
|
1997-08-29 |
2005-10-11 |
Human Genome Sciences, Inc. |
Follistatin-3
|
WO1999018212A1
(fr)
|
1997-10-03 |
1999-04-15 |
Chugai Seiyaku Kabushiki Kaisha |
Anticorps humain naturel
|
US6696411B1
(en)
|
1998-04-22 |
2004-02-24 |
Cornell Research Foundation, Inc. |
Canine erythropoietin gene and recombinant protein
|
EP1113799A4
(en)
|
1998-09-17 |
2004-06-09 |
Lilly Co Eli |
PROTEIN-BASED PREPARATION
|
DE69934995T2
(de)
|
1998-09-22 |
2007-11-22 |
Long Yu |
Für den menschlichen wachstums-differenzierungsfaktor kodierende sequenz und polypeptid, welches durch solche dna-sequenz kodiert wird und verfahren zur herstellung
|
US6472179B2
(en)
|
1998-09-25 |
2002-10-29 |
Regeneron Pharmaceuticals, Inc. |
Receptor based antagonists and methods of making and using
|
US6548634B1
(en)
|
1998-09-30 |
2003-04-15 |
Chiron Corporation |
Synthetic peptides having FGF receptor affinity
|
US6238860B1
(en)
|
1998-11-05 |
2001-05-29 |
Dyax Corp. |
Binding moieties for human parvovirus B19
|
US6777205B1
(en)
|
1998-11-06 |
2004-08-17 |
Sterrenbeld Biotechnologie North America, Inc. |
Host cells expressing recombinant human erythropoietin
|
US20040009535A1
(en)
|
1998-11-27 |
2004-01-15 |
Celltech R&D, Inc. |
Compositions and methods for increasing bone mineralization
|
CN100567322C
(zh)
|
1999-01-21 |
2009-12-09 |
梅塔莫菲克斯公司 |
抑制生长分化因子活性的多肽及表达该多肽的细胞
|
US6914128B1
(en)
|
1999-03-25 |
2005-07-05 |
Abbott Gmbh & Co. Kg |
Human antibodies that bind human IL-12 and methods for producing
|
AU777783B2
(en)
|
1999-04-19 |
2004-10-28 |
Kyowa Hakko Kogyo Co. Ltd. |
Proliferation inhibitor for androgen-independent tumor
|
US6468543B1
(en)
|
1999-05-03 |
2002-10-22 |
Zymogenetics, Inc. |
Methods for promoting growth of bone using ZVEGF4
|
SK8292002A3
(en)
|
1999-11-12 |
2002-12-03 |
Maxygen Holdings Ltd |
A conjugate exhibiting interferon gamma activity, nucleotide sequence encoding for a polypeptide fraction of conjugate, an expression vector and a host cell containing nucleotide sequence, pharmaceutical composition comprising the same and use thereof
|
AU777166B2
(en)
|
1999-12-15 |
2004-10-07 |
Research Development Foundation |
Betaglycan as an inhibin receptor and uses thereof
|
US20030224501A1
(en)
|
2000-03-17 |
2003-12-04 |
Young Paul E. |
Bone morphogenic protein polynucleotides, polypeptides, and antibodies
|
JP4487376B2
(ja)
|
2000-03-31 |
2010-06-23 |
味の素株式会社 |
腎疾患治療剤
|
PT1311285E
(pt)
|
2000-05-15 |
2005-06-30 |
Hoffmann La Roche |
Composicao farmaceutica liquida contendo um derivado de eritropoietina
|
US6627424B1
(en)
|
2000-05-26 |
2003-09-30 |
Mj Bioworks, Inc. |
Nucleic acid modifying enzymes
|
US20030215913A1
(en)
|
2000-07-19 |
2003-11-20 |
Enrique Alvarez |
Nucleic acids, vectors, host cells, polypeptides, and uses thereof
|
US6632180B1
(en)
|
2000-09-07 |
2003-10-14 |
John H. Laragh |
Method for evaluating and treating hypertension
|
DE10045591A1
(de)
|
2000-09-15 |
2002-04-04 |
Klaus Pfizenmaier |
Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine)
|
CA2418835A1
(en)
|
2000-10-16 |
2002-04-25 |
Phylos, Inc. |
Protein scaffolds for antibody mimics and other binding proteins
|
US7087224B2
(en)
|
2000-10-31 |
2006-08-08 |
Amgen Inc. |
Method of treating anemia by administering IL-1ra
|
EP1345959B1
(en)
|
2000-11-20 |
2011-05-25 |
The Board Of Trustees Of The University Of Illinois |
Membrane scaffold proteins
|
US20030082233A1
(en)
|
2000-12-01 |
2003-05-01 |
Lyons Karen M. |
Method and composition for modulating bone growth
|
EP1370287A2
(en)
|
2000-12-01 |
2003-12-17 |
Wyeth |
Method and composition for modulating bone growth
|
US20030133939A1
(en)
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
TW200526779A
(en)
|
2001-02-08 |
2005-08-16 |
Wyeth Corp |
Modified and stabilized GDF propeptides and uses thereof
|
US20040132675A1
(en)
|
2002-02-08 |
2004-07-08 |
Calvin Kuo |
Method for treating cancer and increasing hematocrit levels
|
US7294472B2
(en)
|
2001-03-14 |
2007-11-13 |
Caden Biosciences |
Method for identifying modulators of G protein coupled receptor signaling
|
WO2002074340A1
(fr)
|
2001-03-16 |
2002-09-26 |
Takeda Chemical Industries, Ltd. |
Procede de fabrication d'une preparation a liberation continue
|
AU2002256371B2
(en)
|
2001-04-26 |
2008-01-10 |
Amgen Mountain View Inc. |
Combinatorial libraries of monomer domains
|
DK1436003T3
(da)
|
2001-05-24 |
2010-03-15 |
Zymogenetics Inc |
TACI-immunoglobulin-fusionsproteiner
|
IL159015A0
(en)
|
2001-05-25 |
2004-05-12 |
Genset Sa |
Polypeptides, their preparation and use
|
AUPR638101A0
(en)
|
2001-07-13 |
2001-08-09 |
Bioa Pty Limited |
Composition and method for treatment of disease
|
US6855344B2
(en)
|
2001-07-17 |
2005-02-15 |
Integrated Chinese Medicine Holdings, Ltd. |
Compositions and methods for prostate and kidney health and disorders, an herbal preparation
|
AU2002318743B2
(en)
|
2001-07-17 |
2008-02-21 |
Teijin Limited |
Method of selecting substance characterized by assaying PPARD activating effect and drug
|
KR100453877B1
(ko)
|
2001-07-26 |
2004-10-20 |
메덱스젠 주식회사 |
연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 TNFR/Fc 융합 단백질, 상기 단백질을 코딩하는 DNA, 상기 DNA를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
|
US7320789B2
(en)
|
2001-09-26 |
2008-01-22 |
Wyeth |
Antibody inhibitors of GDF-8 and uses thereof
|
US6784154B2
(en)
|
2001-11-01 |
2004-08-31 |
University Of Utah Research Foundation |
Method of use of erythropoietin to treat ischemic acute renal failure
|
CN102526044A
(zh)
|
2001-12-06 |
2012-07-04 |
法布罗根股份有限公司 |
提高内源性红细胞生成素(epo)的方法
|
US20030144203A1
(en)
|
2001-12-19 |
2003-07-31 |
Voyager Pharmaceutical Corporation |
Methods for slowing senescence and treating and preventing diseases associated with senescence
|
US20060234918A1
(en)
|
2001-12-19 |
2006-10-19 |
Voyager Pharmaceutical Corporation |
Methods for treating and preventing cancers that express the hypothalamic-pituitary-gonadal axis of hormones and receptors
|
US6998118B2
(en)
|
2001-12-21 |
2006-02-14 |
The Salk Institute For Biological Studies |
Targeted retrograde gene delivery for neuronal protection
|
US20030224397A1
(en)
|
2002-02-11 |
2003-12-04 |
Genentech, Inc. |
Antibody variants with faster antigen association rates
|
AU2003217612A1
(en)
|
2002-02-21 |
2003-09-09 |
Wyeth |
GASP1: a follistatin domain containing protein
|
JP4429728B2
(ja)
|
2002-02-21 |
2010-03-10 |
ワイス エルエルシー |
フォリスタチン(follistatin)ドメイン含有タンパク質
|
US20030219846A1
(en)
|
2002-02-28 |
2003-11-27 |
Pfizer Inc. |
Assay for activity of the ActRIIB kinase
|
AU2003232485A1
(en)
|
2002-04-18 |
2003-10-27 |
Mtm Laboratories Ag |
Neopeptides and methods useful for detection and treatment of cancer
|
DE10234192B4
(de)
|
2002-07-26 |
2009-11-26 |
Epoplus Gmbh Co.Kg |
Verwendung von Erythropoetin
|
KR20050083635A
(ko)
|
2002-08-16 |
2005-08-26 |
와이어쓰 |
Bmp-2 에스트로겐 반응 요소 및 이의 사용 방법
|
EP1551385A4
(en)
|
2002-10-15 |
2008-10-22 |
Celgene Corp |
SELECTIVE CYTOKINE INHIBITOR DRUGS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES
|
US7261893B2
(en)
|
2002-10-22 |
2007-08-28 |
Wyeth |
Neutralizing antibodies against GDF-8 and uses therefor
|
US20040223966A1
(en)
|
2002-10-25 |
2004-11-11 |
Wolfman Neil M. |
ActRIIB fusion polypeptides and uses therefor
|
AU2002953327A0
(en)
|
2002-12-12 |
2003-01-09 |
Monash University |
Methods of diagnosing prognosing and treating activin associated diseases and conditions
|
WO2004064770A2
(en)
|
2003-01-17 |
2004-08-05 |
Government Of The United States Of America As Represented By The Secretary, Department Of Health Andhuman Services |
Use of smad3 inhibitor in the treatment of fibrosis dependent on epithelial to mesenchymal transition as in the eye and kidney
|
ES2255467T3
(es)
|
2003-02-07 |
2009-05-01 |
Prometic Biosciences Inc. |
Acidos grasos de cadena de longitud media, gliceridos y analogos como estimuladores de eritropoyesis.
|
US20040197828A1
(en)
|
2003-03-26 |
2004-10-07 |
Gaddy Dana P. |
Method for diagnosis and treatment of bone turnover
|
US20070184052A1
(en)
|
2003-05-09 |
2007-08-09 |
Lin Herbert Y |
Soluble tgf-b type III receptor fusion proteins
|
RU2322261C2
(ru)
|
2003-06-02 |
2008-04-20 |
Уайт |
Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний
|
EP1636270B1
(en)
|
2003-06-16 |
2016-07-20 |
UCB Pharma S.A. |
Antibodies specific for sclerostin and methods for increasing bone mineralization
|
US7611465B2
(en)
|
2003-07-15 |
2009-11-03 |
Board Of Regents, The University Of Texas System |
Rapid and accurate detection of bone quality using ultrasound critical angle reflectometry
|
WO2005009460A2
(en)
|
2003-07-25 |
2005-02-03 |
Medexis, S.A. |
Pharmaceutical composition comprising activin a, alk-4 or derivatives thereof for the treatment of ophthalmic disorders or cancer
|
DE10335211A1
(de)
|
2003-08-01 |
2005-02-17 |
Robert Bosch Gmbh |
Kraftstoff-Einspritzvorrichtung für eine Brennkraftmaschine
|
WO2005025601A1
(en)
|
2003-09-15 |
2005-03-24 |
Monash University |
Follistatin isoforms and uses thereof
|
US8895540B2
(en)
|
2003-11-26 |
2014-11-25 |
DePuy Synthes Products, LLC |
Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
|
AU2005206277B2
(en)
|
2004-01-22 |
2011-06-23 |
Merck Patent Gmbh |
Anti-cancer antibodies with reduced complement fixation
|
US20050197292A1
(en)
|
2004-01-30 |
2005-09-08 |
Glennda Smithson |
Compositions and methods for treating T-cell mediated pathological conditions
|
US7625867B2
(en)
|
2004-03-26 |
2009-12-01 |
Acceleron Pharma Inc. |
BMP-3 propeptides and related methods
|
EP1730186A2
(en)
|
2004-03-31 |
2006-12-13 |
Xencor, Inc. |
Bmp-7 variants with improved properties
|
WO2005113590A2
(en)
|
2004-05-12 |
2005-12-01 |
Acceleron Pharma Inc. |
Bmp10 propeptides and related methods
|
CA2572330A1
(en)
|
2004-06-24 |
2006-01-05 |
Acceleron Pharma Inc. |
Gdf3 propeptides and related methods
|
EP2332977B1
(en)
|
2004-07-23 |
2015-11-25 |
Acceleron Pharma Inc. |
ActRII receptor polypeptides
|
US8617815B2
(en)
|
2004-08-05 |
2013-12-31 |
The Regents Of The University Of California |
Molecules with effects on cellular development and function
|
EP1778275A2
(en)
|
2004-08-12 |
2007-05-02 |
Wyeth |
Combination therapy for diabetes, obesity, and cardiovascular diseases using gdf-8 inhibitors
|
EP1804824B1
(en)
|
2004-09-29 |
2017-01-04 |
Icahn School of Medicine at Mount Sinai |
Fsh and fsh receptor modulator compositions and methods for inhibiting osteoclastic bone resorption and bone loss in osteoporosis
|
WO2006052842A2
(en)
|
2004-11-09 |
2006-05-18 |
The Trustees Of The University Of Pennsylvania |
Methods for diagnosis of myelodysplastic syndromes (mds)
|
CA2587424A1
(en)
|
2004-11-16 |
2006-05-26 |
Avidia Research Institute |
Protein scaffolds and uses thereof
|
NZ538097A
(en)
|
2005-02-07 |
2006-07-28 |
Ovita Ltd |
Method and compositions for improving wound healing
|
WO2006088972A2
(en)
|
2005-02-16 |
2006-08-24 |
The General Hospital Corporation |
Use of modulatirs of compounds of tgf-beta superfamily to regulate hepcidin-mediated iron metabolism
|
WO2006115274A1
(ja)
|
2005-04-26 |
2006-11-02 |
Ajinomoto Co., Inc. |
骨髄赤血球前駆細胞分化促進剤
|
JP2007099764A
(ja)
|
2005-09-09 |
2007-04-19 |
Ajinomoto Co Inc |
血糖低下剤
|
EP1931697B1
(en)
|
2005-09-28 |
2010-09-15 |
ZymoGenetics, Inc. |
Il-17a and il-17f antagonists and methods of using the same
|
US8067562B2
(en)
|
2005-11-01 |
2011-11-29 |
Amgen Inc. |
Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
|
DK1973559T3
(da)
|
2005-11-23 |
2013-03-25 |
Acceleron Pharma Inc |
Activin-ActRIIa antagonister samt anvendelser til fremme af knoglevækst
|
US8128933B2
(en)
|
2005-11-23 |
2012-03-06 |
Acceleron Pharma, Inc. |
Method of promoting bone growth by an anti-activin B antibody
|
CA2632544C
(en)
|
2005-12-06 |
2014-09-23 |
Amgen Inc. |
Use of myostatin antagonist for treating the effects of hypogonadism
|
EP1966183A4
(en)
|
2005-12-20 |
2010-12-29 |
Merck Frosst Canada Ltd |
HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A-DELTA-9-DESATURASE
|
CA2634940A1
(en)
|
2005-12-21 |
2007-07-05 |
Schering Corporation |
Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and h3 receptor antagonist/inverse agonist
|
WO2007076127A2
(en)
|
2005-12-22 |
2007-07-05 |
Biogen Idec Ma Inc |
Condensed imidazoles or pyrazoles and their use as transforming growth factor modulators
|
EP2016423B1
(en)
|
2006-01-20 |
2011-07-13 |
Beckman Coulter, Inc. |
Methods of detection of iron deficiency
|
US7820721B2
(en)
|
2006-01-25 |
2010-10-26 |
Wellstat Therapeutics Corporation |
Compounds for the treatment of metabolic disorders
|
WO2007101060A2
(en)
|
2006-02-28 |
2007-09-07 |
Wellstat Therapeutics Corporation |
Compounds for the treatment of metabolic disorders
|
US8008074B2
(en)
*
|
2006-03-20 |
2011-08-30 |
The Uab Research Foundation |
Compositions and methods for improving bone mass through modulation of receptors of PTH and fragments thereof
|
WO2007120767A2
(en)
|
2006-04-14 |
2007-10-25 |
Amgen Inc. |
Agonist erythropoietin receptor antibodies
|
WO2007123391A1
(en)
|
2006-04-20 |
2007-11-01 |
Academisch Ziekenhuis Leiden |
Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene.
|
CA2652235A1
(en)
|
2006-05-09 |
2007-11-22 |
Hemaquest Pharmaceuticals, Inc. |
Methods for treating blood disorders
|
CN104095838A
(zh)
|
2006-07-21 |
2014-10-15 |
莱因实验室公司 |
醋酸钙的液体组合物
|
GB0615129D0
(en)
|
2006-07-29 |
2006-09-06 |
Univ Cardiff |
Anti-cancer activity of BMP-9 and BMP-10 and their use in cancer therapies
|
WO2008030367A2
(en)
|
2006-09-01 |
2008-03-13 |
The General Hospital Corporation |
Selective myostatin inhibitors
|
CL2007002567A1
(es)
|
2006-09-08 |
2008-02-01 |
Amgen Inc |
Proteinas aisladas de enlace a activina a humana.
|
US7547781B2
(en)
|
2006-09-11 |
2009-06-16 |
Curis, Inc. |
Quinazoline based EGFR inhibitors containing a zinc binding moiety
|
JP5468187B2
(ja)
|
2006-09-26 |
2014-04-09 |
ポリプラスチックス株式会社 |
ポリアセタール樹脂組成物
|
WO2008060139A1
(en)
|
2006-11-17 |
2008-05-22 |
Erasmus University Medical Center Rotterdam |
Methods for controlling mineralization of extracellular matrix, therapeutic methods based thereon and medicaments for use therein
|
US20100003190A1
(en)
|
2006-12-08 |
2010-01-07 |
Caritas St. Elizabeth's Medical Center Of Boston, Inc. |
Method for protecting renal tubular epithelial cells from radiocontrast nephropathy (RCN)
|
EP2103628A4
(en)
|
2006-12-14 |
2012-02-22 |
Forerunner Pharma Res Co Ltd |
MONOCLONAL ANTIBODY ANTI-CLAUDIN 3, AND TREATMENT AND DIAGNOSIS OF CANCER USING SUCH ANTIBODY
|
US20100028332A1
(en)
|
2006-12-18 |
2010-02-04 |
Acceleron Pharma Inc. |
Antagonists of actriib and uses for increasing red blood cell levels
|
US8895016B2
(en)
|
2006-12-18 |
2014-11-25 |
Acceleron Pharma, Inc. |
Antagonists of activin-actriia and uses for increasing red blood cell levels
|
CN104524548A
(zh)
|
2006-12-18 |
2015-04-22 |
阿塞勒隆制药公司 |
活化素-actrii拮抗剂及在提高红细胞水平中的用途
|
CN103920139B
(zh)
|
2007-02-01 |
2018-02-02 |
阿塞勒隆制药公司 |
活化素‑actriia拮抗剂及在治疗或预防乳腺癌中的用途
|
TWI782836B
(zh)
*
|
2007-02-02 |
2022-11-01 |
美商艾瑟勒朗法瑪公司 |
衍生自ActRIIB的變體與其用途
|
TWI459963B
(zh)
|
2007-02-09 |
2014-11-11 |
Acceleron Pharma Inc |
包含ActRIIa-Fc融合蛋白的醫藥組合物;ActRIIa-Fc融合蛋白於治療或預防與癌症相關的骨質流失之用途;ActRIIa-Fc融合蛋白於治療或預防多發性骨髓瘤之用途
|
US8501678B2
(en)
|
2007-03-06 |
2013-08-06 |
Atara Biotherapeutics, Inc. |
Variant activin receptor polypeptides and uses thereof
|
TW201718635A
(zh)
|
2007-03-06 |
2017-06-01 |
安美基公司 |
變異之活動素受體多肽及其用途
|
EP2150560A1
(en)
|
2007-06-01 |
2010-02-10 |
Wyeth |
Methods and compositions for modulating bmp-10 activity
|
WO2009009059A1
(en)
|
2007-07-09 |
2009-01-15 |
Biogen Idec Ma Inc. |
Spiro compounds as antagonists of tgf-beta
|
GB0715087D0
(en)
|
2007-08-03 |
2007-09-12 |
Summit Corp Plc |
Drug combinations for the treatment of duchenne muscular dystrophy
|
JP2010535708A
(ja)
|
2007-08-03 |
2010-11-25 |
ビオマリン アイジーエー リミテッド |
デュシェンヌ型筋ジストロフィーの治療のための薬物併用
|
GB0715938D0
(en)
|
2007-08-15 |
2007-09-26 |
Vastox Plc |
Method of treatment of duchenne muscular dystrophy
|
WO2009025651A1
(en)
|
2007-08-17 |
2009-02-26 |
University Of Maine System Board Of Trustees |
Biologically active peptide and method of using the same
|
US20100279409A1
(en)
|
2007-09-13 |
2010-11-04 |
Neil Robson |
Method for modifying celluar immune resonse by modulating activin activity
|
CN107412734A
(zh)
|
2007-09-18 |
2017-12-01 |
阿塞勒隆制药公司 |
活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途
|
PE20091163A1
(es)
|
2007-11-01 |
2009-08-09 |
Wyeth Corp |
Anticuerpos para gdf8
|
KR20100099193A
(ko)
|
2007-11-21 |
2010-09-10 |
암젠 인크 |
Wise 결합 항체 및 에피토프
|
CA2718403A1
(en)
*
|
2008-03-13 |
2009-09-17 |
The General Hospital Corporation |
Inhibitors of the bmp signaling pathway
|
WO2009146148A2
(en)
|
2008-04-04 |
2009-12-03 |
Tactair Fluid Controls, Inc. |
Locking mechanism with bi-modal actuator
|
US20110104133A1
(en)
|
2008-05-06 |
2011-05-05 |
Joslin Diabetes Center, Inc. |
Methods and compositions for inducing brown adipogenesis
|
WO2009137075A1
(en)
|
2008-05-06 |
2009-11-12 |
Acceleron Pharma Inc. |
Anti-activin antibodies and uses for promoting bone growth
|
US20100087486A1
(en)
|
2008-05-30 |
2010-04-08 |
Hiroshi Nakamura |
Methods for using tgf-b receptor inhibitors or activin-like kinase (alk) 5 inhibitors a-83-01 and sb-431542 to treat eye disease and wound healing conditions
|
KR20190049912A
(ko)
|
2008-06-26 |
2019-05-09 |
악셀레론 파마 인코포레이티드 |
액티빈-actriia의 길항물질 및 적혈구 수준을 증가시키기 위한 이들의 용도
|
KR20190128002A
(ko)
|
2008-06-26 |
2019-11-13 |
악셀레론 파마 인코포레이티드 |
액티빈-actriia 길항물질을 투약하는 방법 및 치료된 환자의 모니터링
|
US8637611B2
(en)
|
2008-08-13 |
2014-01-28 |
Designer Molecules, Inc. |
Amide-extended crosslinking compounds and methods for use thereof
|
TWI626945B
(zh)
|
2008-08-14 |
2018-06-21 |
艾瑟勒朗法瑪公司 |
使用gdf阱以增加紅血球水平
|
US8216997B2
(en)
|
2008-08-14 |
2012-07-10 |
Acceleron Pharma, Inc. |
Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
|
WO2010059861A1
(en)
|
2008-11-20 |
2010-05-27 |
University Of Southern California |
Compositions and methods to modulate hair growth
|
NZ627111A
(en)
|
2008-11-26 |
2015-10-30 |
Amgen Inc |
Variants of activin iib receptor polypeptides and uses thereof
|
AU2010204985A1
(en)
|
2009-01-13 |
2011-08-04 |
Acceleron Pharma Inc. |
Methods for increasing adiponectin
|
AU2010210033A1
(en)
*
|
2009-02-05 |
2011-08-04 |
Digna Biotech, S.L. |
Pharmaceutical compositions comprising TGF- beta1 inhibitor peptides
|
US8110355B2
(en)
|
2009-02-20 |
2012-02-07 |
GenRemedy, LLC |
Methods for identifying agents that inhibit cell migration, promote cell adhesion and prevent metastasis
|
EP2419105A4
(en)
|
2009-04-17 |
2012-09-12 |
Summa Health Systems Llc |
USE OF TRANSFORMATION OF GROWTH FACTOR B RECEPTOR INHIBITORS TO SUPPRESS OCULAR HEALING
|
DK2424895T3
(en)
|
2009-04-27 |
2017-12-18 |
Novartis Ag |
Compositions and Methods for Increasing Muscle Growth
|
EP2440576A4
(en)
|
2009-06-08 |
2013-11-20 |
Acceleron Pharma Inc |
PROCESS FOR INCREASING THE NUMBER OF THERMOUS ADIPOCYTES
|
KR20210034684A
(ko)
|
2009-06-12 |
2021-03-30 |
악셀레론 파마 인코포레이티드 |
절두된 ActRIIB-FC 융합 단백질
|
EP3838919A1
(en)
|
2009-08-13 |
2021-06-23 |
Acceleron Pharma Inc. |
Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels
|
KR20120062874A
(ko)
|
2009-09-09 |
2012-06-14 |
악셀레론 파마 인코포레이티드 |
ActRIIb 길항제들와 이의 투약 및 용도
|
US20110129469A1
(en)
|
2009-11-03 |
2011-06-02 |
Acceleron Pharma Inc. |
Methods for treating fatty liver disease
|
EP2501400B1
(en)
|
2009-11-17 |
2017-11-01 |
Acceleron Pharma, Inc. |
Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
|
WO2012027065A2
(en)
|
2010-08-27 |
2012-03-01 |
Celgene Corporation |
Combination therapy for treatment of disease
|
US8580922B2
(en)
|
2011-03-04 |
2013-11-12 |
Shire Human Genetic Therapies, Inc. |
Peptide linkers for polypeptide compositions and methods for using same
|
EP2726099B1
(en)
|
2011-07-01 |
2018-07-25 |
Novartis AG |
Method for treating metabolic disorders
|
EA034563B1
(ru)
|
2011-10-17 |
2020-02-20 |
Акселерон Фарма Инк. |
Способ лечения или предотвращения перегрузки железом у пациента с талассемией
|
WO2013063536A1
(en)
|
2011-10-27 |
2013-05-02 |
Acceleron Pharma, Inc. |
Actriib binding agents and uses thereof
|
US8765385B2
(en)
|
2011-10-27 |
2014-07-01 |
Ravindra Kumar |
Method of detection of neutralizing anti-actriib antibodies
|
CN104023731A
(zh)
|
2011-10-28 |
2014-09-03 |
帕仁塔生物科技有限公司 |
治疗粘液分泌亢进的方法
|
MX358358B
(es)
|
2011-12-19 |
2018-08-15 |
Amgen Inc |
Polipeptidos de receptores de activina variantes y sus usos.
|
WO2013148277A1
(en)
|
2012-03-30 |
2013-10-03 |
Shire Human Genetic Therapies, Inc. |
Subcutaneous administration of iduronate- 2-sulfatase
|
US10501512B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides
|
US9663569B2
(en)
|
2012-06-14 |
2017-05-30 |
The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center |
Use of blocking agents of bone morphogenic protein (BMP) signalling for the treatment of neuroinflammatory and neurodegenerative diseases
|
JP6298762B2
(ja)
|
2012-07-02 |
2018-03-20 |
協和発酵キリン株式会社 |
抗bmp9抗体を有効成分とする、腎性貧血、がん性貧血などの貧血に対する治療剤
|
CN112933223A
(zh)
|
2012-10-24 |
2021-06-11 |
细胞基因公司 |
用于治疗贫血的方法
|
CN113604550A
(zh)
|
2012-10-24 |
2021-11-05 |
细胞基因公司 |
用于治疗贫血症的生物标志物
|
WO2014064292A1
(en)
|
2012-10-26 |
2014-05-01 |
Universite Pierre Et Marie Curie (Paris 6) |
A method for preventing or treating atrial fibrillation
|
KR102279522B1
(ko)
|
2012-11-02 |
2021-07-19 |
셀진 코포레이션 |
골 및 다른 장애를 치료하기 위한 액티빈-actrii 길항제 및 용도
|
MX2015005839A
(es)
|
2012-11-08 |
2015-12-17 |
Clearside Biomedical Inc |
Metodos y dispositivos para el tratamiento de trastornos oculares en sujetos humanos.
|
CN103047581B
(zh)
|
2012-12-04 |
2015-04-01 |
京东方科技集团股份有限公司 |
背光模组及具有该背光模组的显示装置
|
WO2014093531A1
(en)
|
2012-12-11 |
2014-06-19 |
Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center |
Modulation of myofiber repair by anti-myostatin in strategies with stem cells
|
US20140220033A1
(en)
|
2013-02-01 |
2014-08-07 |
Santa Maria Biotherapeutics, Inc. |
Administration of an Anti-Activin-A Compound to a Subject
|
TW201920262A
(zh)
|
2013-07-30 |
2019-06-01 |
美商再生元醫藥公司 |
抗活化素a之抗體及其用途
|
SG11201600212VA
(en)
|
2013-08-14 |
2016-02-26 |
Novartis Ag |
Methods of treating sporadic inclusion body myositis
|
JP2017505428A
(ja)
|
2013-12-16 |
2017-02-16 |
パランタ バイオサイエンス リミテッド |
診断及び治療の方法
|
EP3094751A4
(en)
|
2014-01-14 |
2017-06-07 |
Santa Maria Biotherapeutics, Inc. |
Activin inhibitor response prediction and uses for treatment
|
CN105992951A
(zh)
|
2014-01-27 |
2016-10-05 |
诺华股份有限公司 |
预测肌萎缩的生物标志物、方法和用途
|
KR20160127148A
(ko)
|
2014-03-21 |
2016-11-02 |
악셀레론 파마 인코포레이티드 |
액티빈 b 및/또는 gdf11을 억제함으로써 적혈 혈액 세포 수준을 증가시키고 비효율적인 적혈구 생성을 치료하는 방법
|
JP6601687B2
(ja)
|
2014-03-31 |
2019-11-06 |
大日本住友製薬株式会社 |
進行性骨化性線維異形成症の予防剤及び治療剤
|
ES2845650T3
(es)
|
2014-04-18 |
2021-07-27 |
Acceleron Pharma Inc |
Procedimientos para aumentar los niveles de glóbulos rojos y tratar la drepanocitosis
|
TW201622746A
(zh)
|
2014-04-24 |
2016-07-01 |
諾華公司 |
改善或加速髖部骨折術後身體復原之方法
|
EP3154566B1
(en)
|
2014-06-13 |
2022-08-03 |
Acceleron Pharma Inc. |
Actrii antagonist for the treatment or prevention of a cutaneous ulcer in a subject that has anemia
|
MX2016016281A
(es)
|
2014-06-13 |
2017-03-31 |
Santa Maria Biotherapeutics Inc |
Polipeptidos receptores formulados y metodos relacionados.
|
MA41052A
(fr)
|
2014-10-09 |
2017-08-15 |
Celgene Corp |
Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
|
HUE062189T2
(hu)
|
2014-12-03 |
2023-09-28 |
Celgene Corp |
Aktivin-ACTRII-antagonisták és alkalmazások mielodiszpláziás szindróma kezelésére
|
MA41119A
(fr)
|
2014-12-03 |
2017-10-10 |
Acceleron Pharma Inc |
Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
|
JOP20160092B1
(ar)
|
2015-05-13 |
2023-03-28 |
Celgene Corp |
علاج البيتا ثلاسيميا باستخدام مصطبة لجائنية
|
EP3298034A4
(en)
|
2015-05-20 |
2019-02-13 |
Celgene Corporation |
IN VITRO CELL CULTURE PROCEDURE FOR BETA THALASSEMIA BY MEANS OF ACTIVIN TYPE II RECEPTOR LIGANDS
|
AU2016301380B2
(en)
|
2015-08-04 |
2021-07-01 |
Acceleron Pharma Inc. |
Methods for treating myeloproliferative disorders
|
US11123430B2
(en)
|
2015-11-04 |
2021-09-21 |
Acceleron Pharma Inc. |
Methods for increasing red blood cell levels and treating ineffective erythropoiesis
|
CA3005975A1
(en)
|
2015-11-23 |
2017-06-01 |
Acceleron Pharma Inc. |
Methods for treating eye disorders
|
MA45811A
(fr)
|
2016-07-27 |
2019-06-05 |
Acceleron Pharma Inc |
Méthodes et compositions de traitement de maladie.
|